Mohammed Arfath Mysore Ismail has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Manohar Mahadev

    Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore, India

    3 shared publications
  • Akhilesh Dubey

    Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore, India

    2 shared publications
  • Akhil Nair

    Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutical Chemistry, Mangaluru 575018, India

    1 shared publication
  • Amitha Shetty

    Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore, India

    1 shared publication
  • Amitha Shetty

    Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore 575018, India

    1 shared publication
  • Geetha Nayak

    Department of Pharmaceutics, ManipalCollege of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India

    1 shared publication

Latest Publications

  • Open Access

    Chitosan-Coated Nanoemulsion for Quercetin Delivery: Formulation Optimisation and Pharmacokinetic Evaluation

    by Mohammed Arfath M. I., Varsha A., Murali Badanthadka, Narayana Charyulu, Manohar Mahadev

    Objective: The present study aimed to develop a chitosan-coated quercetin nanoemulsion (CS-QCT-NE) and to assess its pharmacokinetic performance following oral administration. Methods: A nanoemulsion was formulated using oleic acid as the oil phase, Tween-20 as surfactant, and PEG-200 as cosurfactant. A rotatable central composite design (CCD) with an α value of 1.414 was employed to optimise the nanoemulsion formulation by investigating the influence of organic phase concentration (30-50%), sonication amplitude (20-24%), and sonication time (0-160 s) on globule size (GS), polydispersity index (PDI), and entrapment efficiency (EE). The selected QCT-NE was subsequently coated with low-and medium-molecular-weight chitosan at concentrations of 0.5%, 1.0%, and 1.5% for comparative evaluation, and the 1.5% LMW-coated formulation was empirically selected for further characterisation. It was analysed using transmission electron microscopy (TEM), in vitro drug release testing, and pharmacokinetic and biodistribution studies. Results: The selected CS-QCT-NE exhibited a globule size of 135.4±2.39 nm, PDI of 0.254±0.001, and zeta potential of+26.8±5.97 mV. TEM analysis confirmed spherical droplets with a uniform size distribution. In vitro drug release studies showed 83.72% cumulative drug release in pH 7.4 phosphate buffer within 48 h. Pharmacokinetic assessment showed approximately a 2.43-fold higher systemic exposure, as indicated by AUC0-24, for CS-QCT-NE compared with QCT-PD, corresponding to an exploratory relative oral exposure of 242.8%. Conclusion: The 1.5% LMW chitosan-coated nanoemulsion resulted in higher systemic quercetin (QCT) exposure following oral administration. These pharmacokinetic results are preliminary, and additional studies with a fully validated bioanalytical method are necessary to verify the observed differences.

  • Open Access

    Analytical quality-by-design-assisted RP-HPLC method for simultaneous determination of cinnamaldehyde and chrysin in a lipid-based delivery system and its greenness assessment

    by Mohammed Arfath M I, Sushmitha, Verginia Stefhney Pinto, Amitha Shetty, Akhilesh Dubey, Namdev Dhas, Sri Renukadevi Balusamy, Manohar Mahadev

    Chou-Talalay analysis identified a 1 : 1 CN : CR ratio. RP-HPLC simultaneously quantified CN and CR, and SNEDDS optimisation resulted in rapid self-emulsification, nanosized droplets, and improved bioaccessibility.

  • Open Access

    Phytosomal Delivery of Natural Bioactives: Advancing Bioavailability, Targeted Drug Delivery, and Clinical Translation

    by Mohammed Arfath Mysore Ismail, Akhilesh Dubey, Amitha Shetty, Haribalan Perumalsamy, Sri Renukadevi Balusamy, Seungah Lee, Manohar Mahadev

    Natural bioactive compounds, especially plant-derived phytoconstituents, have gained significant interest due to their structural diversity, multitarget pharmacological activities, and favourable safety profiles. Their pharmaceutical translation is often hindered by poor aqueous solubility, limited membrane permeability, chemical instability, extensive first-pass metabolism, and, therefore, low oral bioavailability. Phytosomes, which are molecular complexes of bioactive compounds with phospholipids, have emerged as a new, effective, lipid-based delivery platform that can overcome these biopharmaceutical limitations and improve solubility, membrane interactions, systemic exposure, and therapeutic efficacy. The present review critically analyses recent advancements in phytosomal drug delivery, from formulation development to clinical translation, focusing on molecular complexation mechanisms, formulation strategies, physicochemical characterisation, pharmacokinetic enhancement, therapeutic applications, and challenges in clinical translation. The current review combines pharmaceutical design principles with recent advances in quality-by-design (QbD), computational formulation optimisation, hybrid phytosomal systems, scalable manufacturing approaches, and targeted delivery strategies. In addition, prospects for the future extension of phospholipid complexation to bioactive compounds from marine organisms, fungi, microorganisms, and algae are discussed in relevance to the next-generation natural product therapeutics. The present review serves as an emerging link between the discovery of natural bioactive compounds and the development of clinically translatable phytosomal systems from a pharmaceutical perspective.

  • Multi-target Agents in Complex Diseases: From Design Principles to Therapeutic Applications

    by Swastika Maity, Mahendra Gowdru Srinivas, Geetha Nayak, Mohammed Arfath M I, Manohar M, Pavithra Pradeep Prabhu, Akhil Nair

    Introduction: Multifactorial complex diseases such as cancer, neurodegeneration, and infections are poorly treated with traditional single-target therapies because biological networks are redundant and adaptively resistant. Methods: A comprehensive literature review was conducted to investigate the theoretical basis, design approaches (pharmacophore linking, fusing, and merging), and clinical uses of multi-target agents using network pharmacology and systems biology. Results: Multi-kinase inhibitors (imatinib, sunitinib, cabozantinib) approved by the Food and Drug Administration have shown superior efficacy to traditional monotherapies due to multiple driver inhibition; dual acetylcholinesterase and Beta-site amyloid precursor protein cleaving enzyme 1 inhibitors show enhanced neuroprotective effects against Alzheimer's disease; and β-lactam/βlactamase inhibitor combinations address drug resistance. Artificial intelligence can accelerate target identification, and novel design technologies, such as fragment-based screening, can generate balanced polypharmacology. Discussion: Multi-target strategies are ideal for overcoming redundancy in biological networks and minimizing drug resistance. However, several issues remain, including the complexity of target selection, the need to achieve balanced efficacy across multiple targets, ADMET optimization, and regulatory hurdles. Emerging technologies, such as quantum computing, precision polypharmacology based on multiomics profiling, and digital health integration, could improve target selection and optimization. Conclusion: Multi-target agents are no longer constrained by single-target effects; however, issues of balanced potency, ADMET, and control still exist. The combination of AI, quantum computing, and precision polypharmacology may enable more effective multi-target interventions to address unmet demands in complex diseases.